Amgen Inc. is a global biotechnology company engaged in the discovery, development, manufacture and commercialization of human therapeutics based on advances in cellular and molecular biology. The company has research programs in metabolic disorders and osteoporosis, inflammation, oncology, neuroscience and hematology.
Amgen is regarded to be the largest independent biotechnology company in the U.S. The company’s main products include: Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), which stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis stimulating agents (ESAs); Neulasta (pegflgrastim) and NEUPOGEN (Filgrastim), which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL (etanercept) that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis.
The company’s research facilities are located in California, Massachusetts, Washington, Canada and Germany. In addition, Amgen operates manufacturing facilities in California, Colorado, Rhode Island, Washington and Puerto Rico. The company markets its products in the United States, Europe, Canada and Australia. The Company was founded in 1980 and is based in Thousand Oaks, California.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment